Orion Capital Management’s Pacira BioSciences PCRX Stock Holding History

Orion Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200	Closed	-$5.84K	–	486
2024 Q1	$5.84K	Hold	200	–	–	﹤0.01%	407
2023 Q4	$6.75K	Hold	200	–	–	﹤0.01%	405
2023 Q3	$6.14K	Buy	+200	New	+$7.21K	﹤0.01%	405
2023 Q2	–	Sell	-200	Closed	-$8.16K	–	350
2023 Q1	$8.16K	Hold	200	–	–	0.01%	378
2022 Q4	$7.72K	Hold	200	–	–	0.01%	325
2022 Q3	$11K	Hold	200	–	–	0.01%	308
2022 Q2	$12K	Hold	200	–	–	0.01%	307
2022 Q1	$15K	Buy	+200	New	+$13.3K	0.01%	303

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Orion Capital Management's PCRX Position: Q2 2024 in Review

Orion Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 200 shares — an estimated $5.84K sold.

Orion Capital Management first reported a position in PCRX in Q1 2022 and held it in 8 quarters. The position peaked at $15K in Q1 2022. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

Orion Capital Management reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
Orion Capital Management sold 200 Pacira BioSciences shares in Q2 2024, an estimated $5.84K.
Orion Capital Management first reported a position in Pacira BioSciences in Q1 2022 and held it in 8 quarters.
Orion Capital Management's Pacira BioSciences position peaked at $15K in Q1 2022.
280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Orion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.